Want to see AU:MYX full AI Analyst Report?

Mayne Pharma Group (MYX) Earnings Dates, Call Summary & Reports

Q: When does Mayne Pharma Group (AU:MYX) report earnings?

Mayne Pharma Group (AU:MYX) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).

Q: What is Mayne Pharma Group (AU:MYX) earnings time?

Mayne Pharma Group (AU:MYX) earnings time is at Aug 20, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is the P/E ratio of Mayne Pharma Group stock?

The P/E ratio of {name} is N/A.

Q: What is AU:MYX EPS forecast?

AU:MYX EPS forecast for the fiscal quarter 2026 (Q4) is -0.3.

53 Followers

Earnings Data

Report Date

Aug 20, 2026

TBA (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

-0.3

Last Year’s EPS

-0.84

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q2 2026

Earnings Call Date:Feb 22, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.

Company Guidance

The guidance from the call is that Mayne will continue to invest selectively to drive market‑share and margin improvement while maintaining cash discipline, aiming to grow Women's Health, scale Dermatology’s disintermediation (next leg planned Q3 FY26) and unlock International value from the NEXTSTELLIS PBS listing and the $18m Salisbury upgrade. Key metrics underpinning that guidance: group H1 revenue was $212.1m with gross margin 65.3% (versus 61.4% PCP), underlying EBITDA $28.6m (‑8% vs PCP) and adjusted operating cash flow from continuing operations $16.9m, with $67.3m cash and marketable securities on hand; reported results excluded a $54.5m non‑cash earn‑out reassessment and $21.3m of diligence/BD/litigation/restructuring charges. Segment targets reflect Women's Health (H1 revenue $96.5m +2%; NEXTSTELLIS demand cycles +16% and net sales USD23.4m +4%; IMVEXXY TRx +3% / net sales USD15.6m +2%; BIJUVA TRx +26% / net sales USD8.2m +23%; ANNOVERA TRx +2% but net sales USD14.4m ‑9% with ~$1.7m returns), Dermatology (H1 revenue $78.6m ‑3% but gross margin 65% up 12ppt and direct contribution $29.8m +35%; branded mix 65% vs 55% PCP) and International (H1 revenue $36.9m ‑1%, gross profit $11.3m +7%, margin 30.5% +3ppt, direct contribution $2.1m ‑42%), plus the 25 million additional U.S. covered lives for NEXTSTELLIS (effective 1 Jan) and an early 118% uplift in NEXTSTELLIS 3‑pack volumes in Dec‑2025; management expects litigation/transaction costs to decline from H1 levels and FDA post‑approval study costs (up ~$2.6m in H1) to step down toward FY27, while also evaluating capital allocation options including buybacks and targeted acquisitions.

Stable Group Revenue and Improved Gross Margin

Group revenue of $212.1 million was broadly flat year‑on‑year while gross margin improved to 65.3% from 61.4% (≈+3.9 percentage points), indicating better mix and margin control.

Improved Total Direct Contribution

Total direct segment contribution increased to $68.1 million, up $3.1 million or ~5% versus the prior corresponding period, reflecting higher-quality earnings despite flat revenue.

Positive Operating Cash Flow and Cash Balance

Adjusted operating cash flow from continuing operations was $16.9 million (cash generative underlying business) and the company closed the half with $67.3 million in cash and marketable securities.

Dermatology Margin-Led Turnaround

Dermatology revenue was $78.6 million (down 3%) but gross margin expanded to 65% (up 12 percentage points) and direct contribution grew 35% to $29.8 million, driven by branded mix (branded revenue $51.2 million, 65% of mix vs 55% PCP).

Women's Health Product Momentum (NEXTSTELLIS, BIJUVA, IMVEXXY)

Women's Health revenue was $96.5 million (+2%). NEXTSTELLIS demand cycles were up 16% with net sales +4% to USD 23.4m; IMVEXXY TRx +3% and net sales +2% to USD 15.6m; BIJUVA TRx +26% and net sales +23% to USD 8.2m—broad-based momentum across the menopause franchise.

International: PBS Listing and Manufacturing Upgrade

NEXTSTELLIS received PBS approval in Australia and promotion commenced; Salisbury facility modernization completed ($18m investment, incl. $4.8m grant). Early indicator: 118% growth in 3-pack NEXTSTELLIS volumes in Dec 2025.

Strategic Repositioning and Leadership Continuity

Company transformation from generics/CDMO to a U.S. branded Women's Health and Dermatology growth company noted as complete; planned CEO succession executed for continuity and the business described as stable with experienced leadership.

Capital Allocation Optionality

Management is evaluating share repurchases, targeted asset acquisitions and promotional investment—indicating flexibility to deploy capital to enhance shareholder value.

Mayne Pharma Group (AU:MYX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AU:MYX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 20, 2026	2026 (Q4)	-0.30 / -	-0.841	―	―	―
Feb 22, 2026	2026 (Q2)	- / -0.15	-0.253	40.71% (+0.10)
Aug 28, 2025	2025 (Q4)	<0.01 / -0.84	0.001	-84200.00% (-0.84)
Feb 25, 2025	2025 (Q2)	-0.13 / -0.25	-0.878	71.18% (+0.63)
Aug 22, 2024	2024 (Q4)	-0.22 / <0.01	-2.005	100.05% (+2.01)
Feb 25, 2024	2024 (Q2)	-0.46 / -0.88	-0.078	-1025.64% (-0.80)
Aug 30, 2023	2023 (Q4)	-0.57 / -2.00	-1.196	-67.64% (-0.81)	―	―
Feb 27, 2023	2023 (Q2)	-0.81 / -0.08	-0.545	85.69% (+0.47)	―	―
Aug 25, 2022	2022 (Q4)	-0.28 / -1.20	-0.035	-3317.14% (-1.16)	―	―
Feb 24, 2022	2022 (Q2)	-0.15 / -0.55	-2.04	73.28% (+1.50)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AU:MYX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 28, 2025	AU$5.03	AU$5.17	+2.78%
Feb 25, 2025	AU$7.22	AU$7.23	+0.14%
Aug 22, 2024	AU$3.94	AU$4.38	+11.17%
Aug 30, 2023	AU$4.75	AU$3.67	-22.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mayne Pharma Group (AU:MYX) report earnings?

Mayne Pharma Group (AU:MYX) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).

What is Mayne Pharma Group (AU:MYX) earnings time?

Mayne Pharma Group (AU:MYX) earnings time is at Aug 20, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Mayne Pharma Group stock?

The P/E ratio of Mayne Pharma Group is N/A.

What is AU:MYX EPS forecast?

AU:MYX EPS forecast for the fiscal quarter 2026 (Q4) is -0.3.